Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.
LIBTAYO globally grew sales to $288.6M, a +23% YoY growth rate. While DUPIXENT sales grew to $3,817M, a +24% YoY growth rate. Importantly, data in the table below reflect net product sales ...
Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. Read More on REGN: Regeneron Pharmaceuticals NewsMORE Related Stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback